Levine, Douglas S.
Eastern Virginia Medical School,
United States
2025 Rank: 102613
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Gastroenterology & Hepatology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1424 out of 108265 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 102613 | 113294 |
| Total Cites | 6788 | 7413 |
| H-index | 39 | 41 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 18 | 18 |
| Total Cites to Single Authored Papers | 198 | 203 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 1586 | 1660 |
| Number of Single+First+Last Authored Papers | 47 | 47 |
| Total Cites to Single+First+Last Authored Papers | 2423 | 2565 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4921 | 5146 |
| Ratio of Total Citations to Distinct Citing Papers | 1.38 | 1.44 |
| Self-Citation Percentage |
8.43%
|
|
Levine, Douglas S.
Ironwood Pharmaceuticals,
United States
2024 Rank: 94642
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Gastroenterology & Hepatology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1322 out of 103730 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 94642 | 105009 |
| Total Cites | 6709 | 7326 |
| H-index | 39 | 41 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 193 | 198 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 1547 | 1614 |
| Number of Single+First+Last Authored Papers | 49 | 49 |
| Total Cites to Single+First+Last Authored Papers | 2415 | 2554 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4850 | 5075 |
| Ratio of Total Citations to Distinct Citing Papers | 1.38 | 1.44 |
| Self-Citation Percentage |
8.42%
|
|
Levine, Douglas S.
Ironwood Pharmaceuticals,
United States
2023 Rank: 87424
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Gastroenterology & Hepatology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1268 out of 98720 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 87424 | 97224 |
| Total Cites | 6628 | 7244 |
| H-index | 39 | 41 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 18 | 18 |
| Total Cites to Single Authored Papers | 192 | 197 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 1524 | 1591 |
| Number of Single+First+Last Authored Papers | 50 | 50 |
| Total Cites to Single+First+Last Authored Papers | 2375 | 2514 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4777 | 5000 |
| Ratio of Total Citations to Distinct Citing Papers | 1.39 | 1.45 |
| Self-Citation Percentage |
8.50%
|
|
Levine, Douglas S.
Ironwood Pharmaceuticals,
United States
2022 Rank: 80806
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Gastroenterology & Hepatology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1172 out of 95371 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 80806 | 89992 |
| Total Cites | 6407 | 7015 |
| H-index | 39 | 41 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 18 | 18 |
| Total Cites to Single Authored Papers | 185 | 190 |
| Number of Single+First Authored Papers | 35 | 35 |
| Total Cites to Single+First Authored Papers | 1450 | 1516 |
| Number of Single+First+Last Authored Papers | 50 | 50 |
| Total Cites to Single+First+Last Authored Papers | 2266 | 2404 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4613 | 4832 |
| Ratio of Total Citations to Distinct Citing Papers | 1.39 | 1.45 |
| Self-Citation Percentage |
8.67%
|
|
Levine, Douglas S.
Ironwood Pharmaceuticals,
United States
2021 Rank: 79783
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Gastroenterology & Hepatology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1157 out of 91513 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 79783 | 89286 |
| Total Cites | 6168 | 6733 |
| H-index | 38 | 40 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 174 | 177 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 1384 | 1442 |
| Number of Single+First+Last Authored Papers | 49 | 49 |
| Total Cites to Single+First+Last Authored Papers | 2174 | 2298 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4463 | 4675 |
| Ratio of Total Citations to Distinct Citing Papers | 1.38 | 1.44 |
| Self-Citation Percentage |
8.39%
|
|
Levine, Douglas S.
Ironwood Pharmaceuticals,
United States
2020 Rank: 72023
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Gastroenterology & Hepatology
SubField 2:
Oncology & Carcinogenesis
Rank in SubField 1: 1088 out of 76367 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 72023 | 80614 |
| Total Cites | 5994 | 6562 |
| H-index | 38 | 40 |
| Hm-index | 13 | 13 |
| Number of Single Authored Papers | 17 | 17 |
| Total Cites to Single Authored Papers | 172 | 175 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 1328 | 1390 |
| Number of Single+First+Last Authored Papers | 48 | 48 |
| Total Cites to Single+First+Last Authored Papers | 2086 | 2214 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4311 | 4526 |
| Ratio of Total Citations to Distinct Citing Papers | 1.39 | 1.45 |
| Self-Citation Percentage |
8.66%
|
|
Related Profiles
Featured Profiles
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.